Development and evaluation of a blocking enzyme-linked immunosorbent assay and virus neutralization assay to detect antibodies to viral hemorrhagic septicemia virus

Anna Wilson, Tony Goldberg, Susan Marcquenski, Wendy Olson, Frederick Goetz, Paul Hershberger, Lucas Hart, Kathy L. Kurth

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

Viral hemorrhagic septicemia virus (VHSV) is a target of surveillance by many state and federal agencies in the United States. Currently, the detection of VHSV relies on virus isolation, which is lethal to fish and indicates only the current infection status. A serological method is required to ascertain prior exposure. Here, we report two serologic tests for VHSV that are nonlethal, rapid, and species independent, a virus neutralization (VN) assay and a blocking enzyme-linked immunosorbent assay (ELISA). The results show that the VN assay had a specificity of 100% and sensitivity of 42.9%; the anti-nucleocapsid-blocking ELISA detected nonneutralizing VHSV antibodies at a specificity of 88.2% and a sensitivity of 96.4%. The VN assay and ELISA are valuable tools for assessing exposure to VHSV.

Original languageEnglish (US)
Pages (from-to)435-442
Number of pages8
JournalClinical and Vaccine Immunology
Volume21
Issue number3
DOIs
StatePublished - Jan 1 2014
Externally publishedYes

Fingerprint

Novirhabdovirus
Immunosorbents
Viruses
Assays
Enzyme-Linked Immunosorbent Assay
Antibodies
Enzymes
Nucleocapsid
Serologic Tests
Fishes
Sensitivity and Specificity
Fish
Infection

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology
  • Clinical Biochemistry
  • Microbiology (medical)

Cite this

Development and evaluation of a blocking enzyme-linked immunosorbent assay and virus neutralization assay to detect antibodies to viral hemorrhagic septicemia virus. / Wilson, Anna; Goldberg, Tony; Marcquenski, Susan; Olson, Wendy; Goetz, Frederick; Hershberger, Paul; Hart, Lucas; Kurth, Kathy L.

In: Clinical and Vaccine Immunology, Vol. 21, No. 3, 01.01.2014, p. 435-442.

Research output: Contribution to journalArticle

Wilson, Anna ; Goldberg, Tony ; Marcquenski, Susan ; Olson, Wendy ; Goetz, Frederick ; Hershberger, Paul ; Hart, Lucas ; Kurth, Kathy L. / Development and evaluation of a blocking enzyme-linked immunosorbent assay and virus neutralization assay to detect antibodies to viral hemorrhagic septicemia virus. In: Clinical and Vaccine Immunology. 2014 ; Vol. 21, No. 3. pp. 435-442.
@article{d845ec61365442e6bc3d88c53b8a987e,
title = "Development and evaluation of a blocking enzyme-linked immunosorbent assay and virus neutralization assay to detect antibodies to viral hemorrhagic septicemia virus",
abstract = "Viral hemorrhagic septicemia virus (VHSV) is a target of surveillance by many state and federal agencies in the United States. Currently, the detection of VHSV relies on virus isolation, which is lethal to fish and indicates only the current infection status. A serological method is required to ascertain prior exposure. Here, we report two serologic tests for VHSV that are nonlethal, rapid, and species independent, a virus neutralization (VN) assay and a blocking enzyme-linked immunosorbent assay (ELISA). The results show that the VN assay had a specificity of 100{\%} and sensitivity of 42.9{\%}; the anti-nucleocapsid-blocking ELISA detected nonneutralizing VHSV antibodies at a specificity of 88.2{\%} and a sensitivity of 96.4{\%}. The VN assay and ELISA are valuable tools for assessing exposure to VHSV.",
author = "Anna Wilson and Tony Goldberg and Susan Marcquenski and Wendy Olson and Frederick Goetz and Paul Hershberger and Lucas Hart and Kurth, {Kathy L.}",
year = "2014",
month = "1",
day = "1",
doi = "10.1128/CVI.00675-13",
language = "English (US)",
volume = "21",
pages = "435--442",
journal = "Clinical and Vaccine Immunology",
issn = "1556-6811",
publisher = "American Society for Microbiology",
number = "3",

}

TY - JOUR

T1 - Development and evaluation of a blocking enzyme-linked immunosorbent assay and virus neutralization assay to detect antibodies to viral hemorrhagic septicemia virus

AU - Wilson, Anna

AU - Goldberg, Tony

AU - Marcquenski, Susan

AU - Olson, Wendy

AU - Goetz, Frederick

AU - Hershberger, Paul

AU - Hart, Lucas

AU - Kurth, Kathy L.

PY - 2014/1/1

Y1 - 2014/1/1

N2 - Viral hemorrhagic septicemia virus (VHSV) is a target of surveillance by many state and federal agencies in the United States. Currently, the detection of VHSV relies on virus isolation, which is lethal to fish and indicates only the current infection status. A serological method is required to ascertain prior exposure. Here, we report two serologic tests for VHSV that are nonlethal, rapid, and species independent, a virus neutralization (VN) assay and a blocking enzyme-linked immunosorbent assay (ELISA). The results show that the VN assay had a specificity of 100% and sensitivity of 42.9%; the anti-nucleocapsid-blocking ELISA detected nonneutralizing VHSV antibodies at a specificity of 88.2% and a sensitivity of 96.4%. The VN assay and ELISA are valuable tools for assessing exposure to VHSV.

AB - Viral hemorrhagic septicemia virus (VHSV) is a target of surveillance by many state and federal agencies in the United States. Currently, the detection of VHSV relies on virus isolation, which is lethal to fish and indicates only the current infection status. A serological method is required to ascertain prior exposure. Here, we report two serologic tests for VHSV that are nonlethal, rapid, and species independent, a virus neutralization (VN) assay and a blocking enzyme-linked immunosorbent assay (ELISA). The results show that the VN assay had a specificity of 100% and sensitivity of 42.9%; the anti-nucleocapsid-blocking ELISA detected nonneutralizing VHSV antibodies at a specificity of 88.2% and a sensitivity of 96.4%. The VN assay and ELISA are valuable tools for assessing exposure to VHSV.

UR - http://www.scopus.com/inward/record.url?scp=84896760347&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84896760347&partnerID=8YFLogxK

U2 - 10.1128/CVI.00675-13

DO - 10.1128/CVI.00675-13

M3 - Article

C2 - 24429071

AN - SCOPUS:84896760347

VL - 21

SP - 435

EP - 442

JO - Clinical and Vaccine Immunology

JF - Clinical and Vaccine Immunology

SN - 1556-6811

IS - 3

ER -